POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine aims to stop Virus-Linked cancers in organ transplant patients
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a vaccine called OSU-2131, designed to help the immune system fight Epstein-Barr virus (EBV). EBV can cause cancers in people who have weakened immune systems, such as those awaiting organ transplants. The study includes healthy volunteers and transpl…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 04, 2026 00:00 UTC
-
Immune cells take aim at Post-Transplant virus
Disease control Recruiting nowThis early-stage study tests a new treatment using specially grown immune cells (EBV-AST cells) to fight EBV infections in people who have had a stem cell transplant. The trial will enroll 18 adults with persistent EBV in their blood. Researchers will test three different doses t…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New immune cell therapy takes on virus after transplant
Disease control Recruiting nowThis early-phase study tests a new treatment for Epstein-Barr virus (EBV) that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to find and destroy virus-infected cells. Up to 18 adult patients who have persistent EBV …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC